{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T17:57:23Z","timestamp":1784138243492,"version":"3.55.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T00:00:00Z","timestamp":1618272000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.clinthera.2021.04.004","type":"journal-article","created":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T12:28:02Z","timestamp":1628252882000},"page":"1066-1078","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Tolerability and Safety of Lasmiditan Treatment in Elderly Patients With Migraine: Post Hoc Analyses From Randomized Studies"],"prefix":"10.1016","volume":"43","author":[{"given":"Vincent T.","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zubair","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen M.","family":"Hochstetler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simin K.","family":"Baygani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula M.","family":"Hauck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashna","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2021.04.004_bib0001","first-page":"S3","article-title":"Migraine: epidemiology, impact, and risk factors for progression","volume":"45","author":"Lipton","year":"2005","journal-title":"Headache"},{"key":"10.1016\/j.clinthera.2021.04.004_bib0002","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","article-title":"Migraine prevalence, disease burden, and the need for preventive therapy","volume":"68","author":"Lipton","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2021.04.004_bib0003","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000494758","article-title":"Prevalence of Migraine in the Elderly: A Narrated Review","volume":"52","author":"Wijeratne","year":"2019","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.clinthera.2021.04.004_bib0004","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","article-title":"Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications","volume":"57","author":"Mangoni","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2021.04.004_bib0005","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s10194-020-01132-3","article-title":"Lasmiditan mechanism of action - review of a selective 5-HT1F agonist","volume":"21","author":"Clemow","year":"2020","journal-title":"J Headache Pain"},{"key":"10.1016\/j.clinthera.2021.04.004_bib0006","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1097\/j.pain.0000000000001801","article-title":"Lasmiditan inhibits calcitonin gene-related peptide release in the rodent trigeminovascular system","volume":"161","author":"Labastida-Ramirez","year":"2020","journal-title":"Pain"},{"key":"10.1016\/j.clinthera.2021.04.004_bib0007","first-page":"103","article-title":"Lasmiditan acts specifically on the 5-HT1F receptor in the central nervous system","volume":"36","author":"Kovalchin","year":"2016","journal-title":"Cephalalgia"},{"key":"10.1016\/j.clinthera.2021.04.004_bib0008","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1177\/0333102410370873","article-title":"Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan","volume":"30","author":"Nelson","year":"2010","journal-title":"Cephalalgia"},{"key":"10.1016\/j.clinthera.2021.04.004_bib0009","doi-asserted-by":"crossref","first-page":"4681","DOI":"10.1111\/bph.14832","article-title":"Characterization of binding, functional activity and contractile responses of the selective 5-HT1F receptor agonist lasmiditan","volume":"176","author":"Rubio-Beltran","year":"2019","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clinthera.2021.04.004_bib0010","first-page":"447","volume":"27","author":"Sessions","year":"2020","journal-title":"European Journal of Neurology"},{"key":"10.1016\/j.clinthera.2021.04.004_bib0011","unstructured":"REYVOWTM (lasmiditan) tablets. [Package insert]. Eli lilly and Company. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/211280s000lbl.pdf Accessed 6 Nov 2019."},{"key":"10.1016\/j.clinthera.2021.04.004_bib0012","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s10194-019-1044-6","article-title":"Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials","volume":"20","author":"Shapiro","year":"2019","journal-title":"J Headache Pain"},{"key":"10.1016\/j.clinthera.2021.04.004_bib0013","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000006641","article-title":"Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study","volume":"91","author":"Kuca","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2021.04.004_bib0014","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/brain\/awz134","article-title":"Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine","volume":"142","author":"Goadsby","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.clinthera.2021.04.004_bib0015","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1177\/0333102419864132","article-title":"Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study)","volume":"39","author":"Brandes","year":"2019","journal-title":"Cephalalgia"},{"key":"10.1016\/j.clinthera.2021.04.004_bib0016","doi-asserted-by":"crossref","DOI":"10.1177\/2515816320958176","article-title":"Long-term safety and efficacy of lasmiditan for acute treatment of migraine: Final results of the GLADIATOR study","volume":"3","author":"Brandes","year":"2020","journal-title":"Cephalalgia Reports"},{"key":"10.1016\/j.clinthera.2021.04.004_bib0017","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1177\/0333102419855080","article-title":"Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN","volume":"39","author":"Krege","year":"2019","journal-title":"Cephalalgia"},{"key":"10.1016\/j.clinthera.2021.04.004_bib0018","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1161\/01.cir.0000437741.48606.98","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Goff","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2021.04.004_bib0019","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1016\/j.jacc.2017.01.064","article-title":"The Aging Cardiovascular System: Understanding It at the Cellular and Clinical Levels","volume":"69","author":"Paneni","year":"2017","journal-title":"J Am Coll Cardiol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821001983?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821001983?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:54:57Z","timestamp":1758963297000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291821001983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0149291821001983"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.04.004","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tolerability and Safety of Lasmiditan Treatment in Elderly Patients With Migraine: Post Hoc Analyses From Randomized Studies","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Eli Lilly and Company. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}